flipper44,
Bids will come sooner. I just don’t want the value of Direct and tissue and indication agnostic designations left out of the equation or you will have exactly what this thread rants against.. a cheap buyout/takeover.
By the way, Celgene and Entremed were brought up by me years ago and relates precisely to what you are describing. ENMD could not find a way to keep going alone for the amount of time needed and Celgene took a position then later the whole company on the cheap. Linda Powers won’t let that happen and hyperopia and I both believe this and understand, like Linda, that it takes time and an educated investor base to create perceived value out of unperceived opportunity.
Three years for max trajectory is not too long to wait. In the mean time let’s get the leukopheresis centers up and running and supply chain issues dealt with. Eventually healthy leukopheresis donors will be in high demand so many investors can eventually make themselves part of the solution and bolster sales by making leukopheresis donations for those in need. Best wishes.
News 
Market Data 
Discover 
